CRISPR & Gene Editing

Last year ended difficulty for publicly traded gene editing companies but at J.P. Morgan’s virtual healthcare conference this week, gene-editing firms are saying that this year will bring exciting developments. Barron's stated: Intellia will expand its clinical trial of the first gene-editing treatment administered directly into patients. The New England...

The breaking news this week in gene editing was Pfizer Inc. will pay as much as $1.35 billion to partner with Beam Therapeutics Inc. on developing drugs for rare genetic diseases using base editing, a technology for manipulating DNA. From Barron's: Gene editing is the next phase of genetic medicine,...

CRISPR & Gene Editing companies are making waves in 2022, including start-ups, which is validating the technology's promise on disrupting healthcare. News coming out of Berlin, Germany and Brisbane, California USA from Bayer AG and Mammoth Biosciences, Inc., is showing how "Big Pharma" is looking to partner with CRISPR start-up...